The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
The placebo response is a major issue in clinical trials for psychiatric disorders. Possible contributing factors to this problem include diagnostic misclassification, issues concerning inclusion/exclusion criteria, outcome measures’ lack of sensitivity to change, measurement errors, poor quality of data entry and verification, waxing and waning of the natural course of illness, regression toward the mean phenomenon, patient and clinician expectations about the trial, study design issues, non-specific therapeutic effects, and high attrition. Over the past few decades, researchers have attempted to reduce the placebo effect in a variety of ways. Unfortunately, approaches with very little or no benefit have included restricting enrollment to selected populations, rater training, requirement of same rater, and placebo lead-in phases. Some benefits, although often marginal, have been derived from standardizing diagnostic procedures, managing clinicians’ overestimation of change, simplification of study visits and assessments, minimizing non-specific, therapeutic effects, extending trial duration, reducing number of sites, increasing the sensitivity of outcome measures, and reducing the number of treatment arms. Thus far, there has been no attempt to develop new study designs aimed at reducing the placebo effect. We are proposing a novel study design, called ‘Sequential Parallel Comparison Design’, suitable for double-blind, placebo-controlled trials in psychiatric disorders. This design is aimed at reducing both the overall placebo response rate and the sample size required for such trials. Its usefulness in clinical research needs to be tested empirically. If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies to mitigate placebo response include increasing study duration, randomizing the run-in period, and addressing functional blinding in rapid-acting antidepressant trials [162]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [162]
Citations
Cites
Linear Statistical Inference and its Applications: Second Editon
Rao, C. R. (1973) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316436 · Cited by 10,489
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“These numbers are even more impressive as most negative trials are typically unpublished, suggesting that the average placebo response rate in MDD trials is probably closer to the 35–45p range.Similarly, in smoking cessation trials, the placebo response rate has progressively increased. For example, in a recent study…”
ResultIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
A Primer on Regression Artifacts
Campbell, D. T., & Kenny, D. A. (1999) · Medical Entomology and Zoology · Cited by 482
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Linear Statistical Inference and its Applications.
Moore, P. G., & Rao, C. R. (1967) · The Statistician · doi:10.2307/2987205 · Cited by 439
Rush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427 · cited 1×
“Another useful approach is to use outcome measures that can be administered in both clinician- and patient-rated forms, as in the case of the Inventory of Depressive Symptomatology (IDS) [”
MethodThe Hamilton Depression Scale: EVALUATION OF OBJECTIVITY USING LOGISTIC MODELS
Bech, P., Allerup, P., Gram, L. F., Reisby, N., Rosenberg, R., Jacobsen, O., & Nagy, A. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00676.x · Cited by 425
Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., Russell, J., Lydiard, R. B., Crits-Christoph, P., Gallop, R., et al. (2001) · JAMA · doi:10.1001/jama.285.15.1978 · Cited by 382
Research works printed but not linked: 2
- 10.1001/jama.271.24.1940 · doi:10.1001/jama.271.24.1940 · Paper page
- 10.1037//0022-006x.70.4.887 · doi:10.1037//0022-006x.70.4.887
Cited by
Items 201–300 of 460
Santen, G. W. E., van Zwet, E. W., Danhof, M., & Pasqua, O. E. D. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.105 · Cited by 18
An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder
Targum, S. D., Cameron, B. R., Ferreira, L., & MacDonald, I. D. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.10.010 · Cited by 18
Dillon, D. G., Belleau, E. L., Origlio, J., McKee, M., Jahan, A., Meyer, A., Souther, M. K., Brunner, D., Kuhn, M., Ang, Y. S., et al. (2024) · Computational Psychiatry · doi:10.5334/cpsy.108 · Cited by 20
Norbury, A., & Seymour, B. (2018) · F1000Research · doi:10.12688/f1000research.13723.2 · Cited by 17
Stevens, J., Bies, R. R., Shekhar, A., & Anand, A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04398.x · Cited by 21
Pritchett, Y., & Tamura, R. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.281 · Cited by 17
“It is known that antidepressant clinical trials are difficult to design since they are subject to a high failure rate [8].”
BackgroundAudio-digital recordings used for independent confirmation of site-based MADRS interview scores
Targum, S. D., Pendergrass, J. C., Toner, C. K., Asgharnejad, M., & BURCH, D. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.016 · Cited by 16
“Beyond the actual efficacy of the candidate drug, clinical trials can fail because of poor study design as well as study execution (Fava et al., 2003).”
A sequential enriched design for target patient population in psychiatric clinical trials
Chen, Y., Zhang, X., Tamura, R., & Chen, C. M. (2014) · Statistics in Medicine · doi:10.1002/sim.6116 · Cited by 16
“In recent years, authors have proposed alternative strategies, including the sequential parallel design (SPD) [6] and two-way enriched design (TED) [7].”
Background“Managing” the Placebo Effect: The Single-Blind Placebo Lead-in Response in Two Pain Models
Harden, R. N., Saraçoğlu, M., Connolly, S., Kirsling, A. J., Comstock, K., Khazey, K., Gerson, T., & Burns, J. W. (2016) · Pain Medicine · doi:10.1093/pm/pnv109 · Cited by 17
Zimmerman, M. A., Clark, H., Multach, M. D., Walsh, E. K., Rosenstein, L. K., & Gazarian, D. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000466 · Cited by 17
“Understanding those aspects of trial design that impact on drug-placebo differences has been a focus of attention,(11,16,17) and suggestions have been made to modify trial design to enhance drug-placebo differences.(18) Symptom severity”
BackgroundAntidepressants and advertising: psychopharmaceuticals in crisis.
Greenslit, N., & Kaptchuk, T. J. (2012) · Europe PMC (PubMed Central) · Cited by 16
Modelling and simulation of placebo effect: application to drug development in schizophrenia
Reddy, V. P., Kozielska, M., de Greef, R., Vermeulen, A., & Proost, J. H. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9296-7 · Cited by 16
“About half of the efficacy failures were due to lack of superiority over placebo treatment, due to high and highly variable placebo effects (PEs) (20– 70 %) [4, 5].”
BackgroundMethodBlinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
What should constitute a control condition in psychedelic drug trials?
Colloca, L., & D, M. F. M. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00321-2 · Cited by 17
“Placebo (and nocebo) responses are influenced by factors such as the nature of the illness, biases, co-interventions and the characteristics of the treatment itself 34,44,45 .”
Nakonezny, P. A., Mayes, T. L., Byerly, M., & Emslie, G. J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.003 · Cited by 16
“The SPCD was proposed for double-blind, placebocontrolled trials in psychiatric disorders to reduce overall placebo response rate and the sample sizes required for such trials (Boessen et al., 2012; Fava et al., 2003; Ivanova et al., 2011).”
BackgroundMethodGoldenholz, D. M., & Goldenholz, S. R. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.033 · Cited by 16
Tedeschini, E., D, M. F. M., Goodness, T. M., & Papakostas, G. I. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.02.004 · Cited by 15
“Another factor which may influence placebo-response rates is patient expectation of improvement which, in turn, may be influenced by several factors such as a positive view of the institution where the study is carried out, any positive experience with previous exposure to the drug treatment, or the presence of an act…”
BackgroundSequential parallel comparison design with binary and time‐to‐event outcomes
Silverman, R. K., Ivanova, A., & Fine, J. P. (2018) · Statistics in Medicine · doi:10.1002/sim.7635 · Cited by 15
“Such multistage designs can be combined with population enrichment as in the placebo lead‐in and the randomized withdrawal designs.(3) Fava et al(3) proposed sequential parallel comparison design (SPCD) that was described as follows in their original paper (they refer to a stage of SPCD as a phase): “The basic idea is…”
MethodPapakostas, G. I., D, M. F. M., Freeman, M. P., Shelton, R. C., Thase, M. E., Jha, M. K., Trivedi, M. H., Dirks, B., Liu, K., & Stankovic, S. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000328 · Cited by 16
“The study used a twostage Sequential Parallel-Comparison Design (Fava et al., 2003).”
MethodStahl, S. M., & Greenberg, G. D. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13000 · Cited by 16
“A variation on this is already suggested by the novel Sequential Parallel design now being more commonly implemented in modern trials with novel statistics where the placebo non-responders are re-randomized to drug or placebo and the placebo responders are dropped out (14).”
BackgroundMethodInnovations in Clinical Research Design and Conduct in Psychiatry: Shifting to Pragmatic Approaches
Marks, D. M., Thanaseelan, J., & Pae, C. (2009) · Psychiatry Investigation · doi:10.4306/pi.2009.6.1.1 · Cited by 14
Jane, J. S., Ralevski, E., Yoon, G., & Petrakis, I. L. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2018.1549764 · Cited by 14
Doubly Randomized Delayed-Start Design for Enrichment Studies with Responders or Nonresponders
Liu, Q., Lim, P., Singh, J. B., Lewin, D., Schwab, B. H., & KENT, J. M. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2012.678234 · Cited by 14
“( 2003 ), which, in comparison to the randomized start design of Leber ( 1996 ), uses enrichment with the placebo nonresponders of the first period for initiation of treatment with the new drug in the second period.”
MethodNovel designs and paradigms to study the placebo response in gastroenterology
Enck, P., Chae, Y., & Elsenbruch, S. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.10.003 · Cited by 14
Tao, F., Esposito, A. A., & Vinciarelli, A. (2020) · Interspeech (USB) · doi:10.21437/interspeech.2020-2888 · Cited by 14
“…treatments and have been shown to be affected by several drawbacks, including the difficulty to interpret placebo-controlled trials [11, 12] methodological pit-falls at the level of patient selection and enrolment [13] or mis-alignment between clinicians’ observations and patients’…”
BackgroundBeyond psychedelics: set and setting in general psychiatric practice
Kozak, Z., & Miller, C. W. T. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2419662 · Cited by 14
“While both have historically been seen as liabilities in psychiatric practice and research (Fava et al., 2003; Mallinckrodt et al., 2011), it is important to acknowledge these factors are staples in conventional treatment.”
Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials.
Smith, E. A., Horan, W. P., Demolle, D., Schueler, P., Fu, D., Anderson, A., Geraci, J., Butlen‐Ducuing, F., Link, J., Khin, N. A., et al. (2022) · PubMed · Cited by 18
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.031 · Cited by 13
“To the extent these numbers indicate the presence of more false negative trials, rising placebo response may delay bringing new treatments to market, increase the costs of drug development, and influence the allocation of private industry resources away from drug development for psychiatric disorders (Fava et al., 200…”
BackgroundZAFONTE, R. D., Fregni, F., Bergin, M. J. G., Goldstein, R., Boudreau, N., Monge, I., Luz, M., Frazier, J., & Giacino, J. T. (2019) · Brain Injury · doi:10.1080/02699052.2019.1677941 · Cited by 14
“absorption (via enteral delivery) were adequate, particularly in the most severely affected individuals (39).”
BackgroundFreeman, M. P., Fava, M., Dirks, B., Jha, M. K., Papakostas, G. I., Shelton, R. C., Thase, M. E., Trivedi, M. H., Liu, K., & Stankovic, S. (2020) · Depression and Anxiety · doi:10.1002/da.23017 · Cited by 14
Ahmadzad-Asl, M., Davoudi, F., Mohamadi, S., Hadi, F., Nejadghaderi, S. A., Mirbehbahani, S. H., Kermani, R. J. N., Saneh, S., Arshadi, M., Naserbakht, M., et al. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211068793 · Cited by 12
“The intersubjective nature of a clinical visit may also involve possible biases (e.g. expectation bias) that may lead subjects to under-report negative mental states and clinicians to under-report objective findings (Fava et al., 2003).”
BackgroundMeasuring Health-Related Quality of Life With Multimodal Data: Viewpoint
Clay, I., Cormack, F. K., Fedor, S., Foschini, L., Gentile, G., Hoof, C. A. V., Kumar, P., Lipsmeier, F., Sano, A., Smarr, B. L., et al. (2022) · Journal of Medical Internet Research · doi:10.2196/35951 · Cited by 13
“[13-15] Background: Anxiety and depression are defined with clinical interviews in RCTsf, possibly inflating intervention’s/placebo’s effects.”
BackgroundFailed efficacy of ziprasidone in the treatment of post-traumatic stress disorder
Ramaswamy, S., Driscoll, D., Smith, L. M., Bhatia, S. C., & Petty, F. (2015) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2015.12.003 · Cited by 12
Remarks on designs enriching for placebo non-responders
Rosenkranz, G. (2016) · Clinical Trials · doi:10.1177/1740774515625186 · Cited by 12
“The sequential parallel comparison design combines a parallel group design with a placebo non-responder enriched second stage.(8) Originally described for binary endpoints, it was extended to continuous data.”
MethodThe Massachusetts General Hospital Guide to Depression: New Treatment Insights and Options
(2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1 · Cited by 12
Boessen, R., Knol, M. J., Groenwold, R. H. H., Grobbee, D. E., & Roes, K. C. B. (2012) · Clinical Trials · doi:10.1177/1740774512456454 · Cited by 12
“High placebo response, common in psychiatric trials, is considered among the main reasons for trial failure [4,5].”
BackgroundMethodInfluentialSoogrim, V., Ruberto, V. L., Murrough, J. W., & Jha, M. K. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s240862 · Cited by 12
Khan, A., Atkinson, S. D., Mezhebovsky, I., She, F., Leathers, T., & Pathak, S. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600102 · Cited by 16
Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder
D, M. F. M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1727 · Cited by 12
Sacchetti, E., Frank, E., Siracusano, A., Racagni, G., Vita, A., & Turrina, C. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000074 · Cited by 11
“Clinical remission has also been considered to be immune from the confounding effect exerted by the law of the initial value (Myrtek and Foerster, 1986; Laird, 1992; Teadlow et al., 1998; Fava et al., 2003).”
BackgroundPlacebos in the era of open‐label trials: An update for clinicians
Sagy, I., Abres, J., Winnick, A. A., & Jotkowitz, A. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13038 · Cited by 12
Montecchi-Palmer, M., Wu, M., Rolando, M., Lau, C., Quinones, V. L. P., & Dana, R. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00720-1 · Cited by 11
“SPC study designs require smaller sample sizes and can help reduce the placebo effect (Table 2) [69].”
BackgroundWhen does the placebo effect have an impact on network meta-analysis results?
Nikolakopoulou, A., Chaimani, A., Furukawa, T. A., Papakonstantinou, T., Rücker, G., & Schwarzer, G. (2023) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2022-112197 · Cited by 11
Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level
Guizzaro, L., Morgan, D. D. V., Falco, A., & Gallo, C. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.04.022 · Cited by 11
Strategies to minimize placebo effects in research investigations
Rodrigues, F. B., & Ferreira, J. J. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.04.002 · Cited by 13
A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response
Goméni, R., Goyal, N., Bressolle, F., & D, M. F. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.105 · Cited by 11
Placebo response in depression: is it rising?
Enck, P. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30308-x · Cited by 11
Statistical inference problems in sequential parallel comparison design
Cui, Y., Ogbagaber, S., & Hung, H. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1609014 · Cited by 11
“To entertain this challenge, the sequential parallel comparison design (SPCD) proposed in Fava et al. (2003) implements two stages in trial design.”
BackgroundMethodResultInfluentialKalaria, S. N., Zhu, H., Farchione, T. R., Mathis, M. V., Gopalakrishnan, M., Uppoor, R. S., Mehta, M., & Younis, I. R. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1501 · Cited by 11
Reiter, J. E., Nickels, S., Nelson, B. W., Rainaldi, E., Peng, L. H., Doraiswamy, P. M., Kapur, R., Abernethy, A. P., & Trister, A. D. (2024) · NPP—Digital Psychiatry and Neuroscience · doi:10.1038/s44277-024-00008-7 · Cited by 10
“More recent designs including the sequential parallel comparison design hope to have more success [34].”
Geijer, J., Baigi, A., & Aiff, H. (2021) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2021.1918240 · Cited by 11
“However, when using the same rater there is a risk of affecting the result since the non-specific therapeutic effects only increase in intensity with the study clinician [10].”
Zilcha‐Mano, S., Wallace, M. L., Brown, P. J., Sneed, J. R., Roose, S. P., & Rutherford, B. R. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01606-1 · Cited by 10
Farmaci antidepressivi nella pratica psichiatrica : efficacia reale
Migone, P. (2005) · doi:10.1400/64882 · Cited by 10
“…possano indurre una sorta di dipendenza e predisporre ad un aumento di recidive e alla cronicità (si vedano ad esempio i lavori di G.A. Fava, 1994, 1995, 2003; per un dibattito, vedi Walsh et al., 2002; M. Fava et al., 2003; Holbrook & Goldsmith, 2003; Portuges, 2003; Moncrieff & Kirsch, 2005).”
BackgroundNeuroimaging Studies of Antidepressant Placebo Effects: Challenges and Opportunities
Brown, V. M., & Peciña, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00669 · Cited by 12
“Despite innovative clinical trial designs (4) and statistical methods (5, 6) aimed at controlling for this source of noise, the neurobiological mechanisms underlying antidepressant placebo effects are unknown.”
BackgroundSuh, H. W., Kim, S., Park, S. J., Hyun, S. H., Lee, S.-Y., Auh, J., Lee, H. J., Cho, S., Kim, J., & Choi, H. (2012) · Food Research International · doi:10.1016/j.foodres.2012.11.009 · Cited by 11
Targum, S. D., BURCH, D. J., Asgharnejad, M., Petersen, T., Goméni, R., & D, M. F. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.003 · Cited by 10
“, 2008; Fava et al., 2012). As noted, our findings support the Merlo-Pich et al. (2010) and Merlo-Pich and Gomeni (2008) hypothesis that posthoc elimination of data from trial sites that generate nonplausible placebo response rates can enhance signal detection.”
BackgroundMethodResultInfluentialTargum, S. D., & Pendergrass, J. C. (2014) · Annals of General Psychiatry · doi:10.1186/s12991-014-0021-3 · Cited by 10
“Numerous factors affect trial outcomes including the effectiveness of the candidate drug, study design, study completion, and trial execution [6-8].”
BackgroundInfluentialGhazanfarpour, M., Najafi, M. N., Sharghi, N. B., Mousavi, M. S., Babakhanian, M., & Rakhshandeh, H. (2018) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.2017.0124 · Cited by 10
“A high placebo effect is often observed in psychiatric (22,23) and nonhormonal trials (24).”
BackgroundGoméni, R., Bressolle, F., & D, M. F. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02443-0 · Cited by 10
“Among these study designs, we can mention the lead-in periods [6] or the sequential parallel comparative design [7].”
MethodPlacebo effect‐adjusted assessment of quality of life in placebo‐controlled clinical trials
Eickhoff, J. C. (2008) · Statistics in Medicine · doi:10.1002/sim.3180 · Cited by 10
Sequential treatment of depression in primary care
Rafanelli, C., Fava, G. A., & Sonino, N. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01342.x · Cited by 10
The Sequential Parallel Comparison Model: A Revolution in the Design of Clinical Trials
Grandi, S. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069737 · Cited by 10
Editorial: Demystifying the Placebo Effect
Murray, E. J. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa162 · Cited by 10
Ethical considerations in the treatment of multiple sclerosis fatigue
Nourbakhsh, B., Waubant, E. L., Evers, A. W. M., & Solomon, A. J. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103129 · Cited by 9
Busl, K. M., Smith, C. R., Troxel, A. B., D, M. F. M., Illenberger, N., Pop, R., Yang, W., Frota, L. M., Gao, H., Shan, G., et al. (2024) · Neurocritical Care · doi:10.1007/s12028-024-02078-z · Cited by 9
“This mitigates a potentially high response to placebo [65], which is important in the setting of a placebo intervention involving a procedure (injection of saline) and patient-reported outcomes—all factors associated with higher placebo effect [66, 67].”
Mi, M., & Betensky, R. A. (2013) · Clinical Trials · doi:10.1177/1740774512468806 · Cited by 9
“Other contributing factors may arise from the actual study itself, such as amount of patient interaction with physicians and effective control of blinding [2].”
BackgroundMethodInfluentialA comparative study with depressed patients on the acceptability of placebo use
Feffer, K., Lichtenberg, P., Becker, G., Bloch, Y., Netzer, R., & Nitzan, U. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2016.05.004 · Cited by 9
Significance of Participants’ Expectations in Managing the Placebo Effect in Antidepressant Research
Ćurković, M., & Košec, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00713 · Cited by 10
“Those include illness heterogeneity, classification systems’ validity, unavailability of objective and meaningful outcome measures, waxing and waning course of illness, industry involvement, and gaps between initiation and the full effect of antidepressants (1, 2, 11, 13, 37, 37, 38, 41, 44).”
BackgroundResultJha, M. K., D, M. F. M., Freeman, M. P., Thase, M. E., Papakostas, G. I., Shelton, R. C., Trivedi, M. H., Dirks, B., Liu, K., & Stankovic, S. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13425 · Cited by 9
Early symptomatic improvement affects treatment outcome in a study of major depressive disorder
Targum, S. D. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.09.009 · Cited by 9
Fedorov, V. V., & Liu, T. (2007) · Wiley eBooks · doi:10.1002/9780471462422.eoct342 · Cited by 10
Bloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., et al. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac055 · Cited by 8
Farabaugh, A. H., Sonawalla, S. B., Fava, M., Pedrelli, P., Papakostas, G. I., Schwartz, F., & Mischoulon, D. (2006) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.765 · Cited by 8
“Since patients’ expectations of improvement are considered one of the key contributing factors to placebo response (Fava et al., 2003; Yang et al., 2005), in the present study we examined whether cognitive factors differ among patients with TDR and PPR.”
BackgroundSelf-citationShelton, R. C., Fava, M., Freeman, M. P., Thase, M. E., Papakostas, G. I., Jha, M. K., Trivedi, M. H., Dirks, B., Liu, K., & Stankovic, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.051 · Cited by 8
Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology
Potter, W. Z., Mallinckrodt, C. H., & Detke, M. J. (2014) · Pharmaceutical Medicine · doi:10.1007/s40290-014-0052-8 · Cited by 8
“2.3 Alternatives to Traditional Parallel-Group Designs A logical extension of the placebo lead-in design strategy, called the sequential parallel comparison design (SPCD) [36], has been employed in several studies.”
MethodInfluentialAdaptive Design - Recent Advancement in Clinical Trials
Chang, M. (2016) · Journal of Bioanalysis & Biostatistics · doi:10.13188/2641-8681.1000003 · Cited by 9
“studied two-stage re-randomization adaptive designs and analyses in trials with high placebo effect [110-112].”
MethodIovieno, N., Tedeschini, E., Levkovitz, Y., Ameral, V., & Papakostas, G. I. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000666 · Cited by 8
“Such 'failed ' or 'negative ' trials may, in turn, lead to delays in bringing new treatments to the clinic, as well as increased costs for the development of new treatments (Fava et al. 2003).”
BackgroundRybin, D. V., Lew, R., Pencina, M. J., D, M. F. M., & Doros, G. D. (2017) · Journal of the American Statistical Association · doi:10.1080/01621459.2017.1375930 · Cited by 8
“The sequential parallel comparison design or SPCD (Fava et al. 2003; Fava and Schoenfeld 2010a, 2010b, 2011, 2012a, 2012b, 2012c) is a novel approach addressing placebo response.”
BackgroundMethodKalaria, S. N., McElroy, S. L., Gobburu, J. V. S., & Gopalakrishnan, M. (2019) · Clinical and Translational Science · doi:10.1111/cts.12682 · Cited by 9
“In the psychiatry setting, it is very difficult to parse out the natural disease course from the large observed placebo effects due to other contributing factors, such as individual regression toward the mean natural state, external factors leading to symptom fluctuation, and/or concurrent psychological intervention.(…”
BackgroundGoméni, R., & Merlo‐Pich, E. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.05.002 · Cited by 8
“2008) and from experts' opinion regarding the clinical knowledge of the disease (Fava et al. 2003; Khan et al. 2007) In Major Depressive Disorders (MDD) depression is commonly measured with rating scales, e.”
BackgroundMethodTaylor, J. J., Szigeti, B., Silverberg, N. D., Ahmadzad-Asl, M., Kare, M. R., Webler, R. D., Orsini, D. K., Rosenblat, J. D., Bschor, T., Baethge, C., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00018-0 · Cited by 7
Evaluation and Treatment of Sleep Complaints: Patients’ Subjective Responses
Hossain, N. K., Irvine, J., Ritvo, P., Driver, H. S., & Shapiro, C. M. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000107569 · Cited by 7
Heo, J.-Y., Jeon, H. J., Fava, M., Mischoulon, D., Baer, L., Clain, A., Doorley, J., Pisoni, A., & Papakostas, G. I. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.01.007 · Cited by 6
“SPCD is a clinical trial design paradigm aimed at reducing both the placebo response rate and sample size requirement (Fava et al., 2003).”
BackgroundMethodInfluentialLopresti, A. L., Smith, S. J., Marx, W., Díez‐Municio, M., & Morán-Valero, M. I. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.05.024 · Cited by 7
Goméni, R., & Bressolle, F. (2025) · Clinical and Translational Science · doi:10.1111/cts.70128 · Cited by 7
Potential Predictors of Placebo Response: Lessons from a Large Database
Entsuah, R., & Vinall, P. (2007) · Drug Information Journal · doi:10.1177/009286150704100304 · Cited by 6
Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders
Srivastava, S., Şahin, M., & Prock, L. A. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00022-9 · Cited by 9
Homma, G., & Daimon, T. (2019) · Biometrical Journal · doi:10.1002/bimj.201800394 · Cited by 6
“…for continuous endpoints (see, e.g., Chen et al., 2011; Doros et al., 2013; Tamura & Huang, 2007; Zhang et al., 2018), binary endpoints (see, e.g., Fava et al., 2003; Huang & Tamura, 2010; Ivanova, Qaqish, & Schoenfeld, 2011; Silverman, Ivanova, & Fine, 2018), time-to-event endpoints (Sil- verman…”
Enrichment designs using placebo nonresponders
Benda, N., & Haenisch, B. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.1992 · Cited by 6
“Under this assumption, since kπN (w ∗, r∗) < k1(w(1), r∗(1)) = 5∕8,∀πN < 1, (13)”
BackgroundInfluentialStatistical methods in handling placebo effect
Raman, R. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.04.004 · Cited by 6
Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path
Taliaz, D., & Serretti, A. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220628103843 · Cited by 6
Zimmerman, M., Clark, H., Multach, M. D., Walsh, E. K., Rosenstein, L. K., & Gazarian, D. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.041 · Cited by 6
“High rates of placebo response and difficulties demonstrating significant differences between active medication and placebo have resulted in a search for strategies to increase the likelihood of detecting an antidepressant signal (Fava et al., 2003; Gelenberg et al., 2008).”
BackgroundThe placebo effect in psychiatry: problem or solution?
Huculak, S. (2013) · Journal of Medical Ethics · doi:10.1136/medethics-2013-101410 · Cited by 6
Lui, K. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217748486 · Cited by 6
Re-evaluation of Significance and the Implications of Placebo Effect in Antidepressant Therapy
Ćurković, M., Košec, A., & Savić, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00143 · Cited by 6
“Moderators and mediators of placebo and antidepressant effects have been thoroughly investigated and reviewed [more thoroughly discussed in: (28, 29)].”
BackgroundPermutation and Bootstrap Testing for the Sequential Parallel Comparison Design
Silverman, R. K., Fine, J. P., Zink, R. C., & Ivanova, A. (2019) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2018.1549095 · Cited by 6
“Therefore unlike the placebo leadin, data from initial stage are used and placebo non-responder data are utilized twice (Fava et al. 2003).”
MethodRising Placebo Response Rates Threaten the Validity of Antipsychotic Meta-Analyses
Dotson, S. J., Mischoulon, D., Lee, H., & D, M. F. M. (2019) · Annals of Clinical Psychiatry · doi:10.1177/154733251903100404 · Cited by 6
Lee, J., & Lee, S. I. (2020) · Journal of Attention Disorders · doi:10.1177/1087054720951868 · Cited by 6
“For parental reports, expectations about the trial outcome can have a significant effect on the degree of placebo response (Fava et al., 2003).”
BackgroundPirlindole in the Treatment of Depression and Fibromyalgia Syndrome
Branco, J., Tomé, A. M., Cruz, M. R., & Filipe, A. (2011) · Clinical Drug Investigation · doi:10.2165/11595410-000000000-00000 · Cited by 6
GREENE, N. M. P., Taylor, E., Gage, S. H., & Munafo, M. R. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03155.x · Cited by 6
“Moreover, there is anecdotal evidence that researchers have attempted to increase the likelihood of obtaining a statistically significant result in trials by reducing the rate of placebo responding [2].”
Background
Metadata
- Authors
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 72
- Issue
- 3
- Pages
- 115-127
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2073526412
- Cited by
- 452
- References
- 34
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 17 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 29 · 2019: 41 · 2018: 23 · 2017: 32 · 2016: 21 · 2015: 29 · 2014: 22 · 2013: 21 · 2012: 22
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, placebo effect, mental illness, clinical trial design, regression to the mean, attrition, sample size reduction, outcome measure sensitivity
- MeSH terms
- Mental Disorders, Clinical Trials as Topic, Double-Blind Method, Humans, Research Design, Reproducibility of Results, Placebo Effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.